Haemonetics Downgraded as Abbott, Cordis Threaten Market Share

Analyst Downgrade: Needham lowered its rating on Haemonetics to <strong class="body_output text-content_primary font-semibold" node="[object Object]">&#x27;Hold&#x27; from &#x27;Buy&#x27; due to mounting competitive pressure.
Market Share Risk: Increased competition from Abbott and Cordis is expected to impact the <strong class="body_output text-content_primary font-semibold" node="[object Object]">Interventional Technologies segment through fiscal year 2027.
Investor Exit: Riverwater Partners has <strong class="body_output text-content_primary font-semibold" node="[object Object]">liquidated its position in Haemonetics, reallocating capital to investments with clearer growth catalysts.

Needham Cuts Haemonetics to 'Hold' on Competitive Threats

Needham downgraded Haemonetics from “Buy” to “Hold” this week, pointing to intensified competition from Abbott and Cordis in the vascular closure device market. The firm warns this pressure could weigh on the company’s Interventional Technologies segment through fiscal year 2027. In a significant move, the firm also removed its price target, undercutting a key catalyst many investors were watching for a recovery in the segment.

Vascular Device Competition Clouds $1.5B Revenue Outlook

The intensified competition creates headwinds for Haemonetics' projected $1.5 billion in revenue and $257.9 million in earnings by 2028. The VASCADE portfolio is a core growth driver, and sustained share loss could pressure margins and slow diversification efforts. Underscoring the rising investor concern, Riverwater Partners also exited its Haemonetics position to seek companies with clearer near-term catalysts. This analyst downgrade and institutional exit force a reassessment of the stock's narrative, even as some estimates project a fair value of $85.91, a 6% upside from its current price.